DiaSorin hit by profit-taking and JPMorgan's "underweight" rating

(Il Sole 24 Ore Radiocor) - Diasorin has been on a rollercoaster ride over the past two trading sessions: after yesterday's rally, with Morgan Stanley upgrading its rating to "overweight" from "equal weight" with a target price increased from €100 to €101, the molecular diagnostics and immunodiagnostics group's stock has fallen more than 4 points. In addition to profit-taking following yesterday's rally, another negative analyst assessment weighs on the stock: JPMorgan initiated coverage with an "underweight" rating and a target price of €75.40, approximately 13% below current levels.

The investment bank cited the structural challenges facing the group, specifically highlighting "its high exposure to immunodiagnostics , where increasing competition and reimbursement pressures represent significant headwinds." JPMorgan's analysis indicates limited room for growth for Diasorin, with EBITDA estimates 7% below consensus for fiscal 2026 and 12% below consensus for 2027. "Although Diasorin shares have already declined 9% year-to-date, reflecting certain risks, the stock still trades at a price-to-earnings ratio of 20.5 times for fiscal 2026, suggesting potential further downside given expected earnings downgrades in the medium term," they said.

Furthermore, according to press rumors reported by Il Sole 24 Ore and Reuters, Diasorin could leave the FTSE MIB as early as the next quarterly review (the deadline for calculating the index update, which is based on market capitalization and share liquidity, expires on Monday). As sources report, Lottomatica Group , which will potentially represent 0.95% of the index, could enter the main listing, displacing either Diasorin (it will drop to around 0.3%) or Pirelli & C (0.35%). At current prices, the ranking parameter is virtually identical, traders explain, making it impossible to determine with certainty which of the two will exit the index.